Comparison of efficacy of Varenicline and transcranial direct current stimulation (tDCS) in smoke cessation

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181026041468N4

Enrollment

106

Registered

2021-08-11

Start date

2021-07-21

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nicotine dependence. Nicotine dependence, cigarettes

Interventions

Intervention 1: In the intervention group, 10 sessions of 2 milliampere stimulation of tDCS will be done for 20 minutes every day. Intervention 2: In the control group, the varenicline tablets will be

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Smokers at the age of 18-65 Having a minimum literacy Informed consent

Exclusion criteria

Exclusion criteria: Request from the patient or the patient's legal guardian to leave the study at any time of the study Occurrence of harmful or intrusive side effects due to Varenicline or tDCS Any contraindications of tDCS Epilepsy Dementia, delirium or other cognitive disorders Any history of psychiatric disorders Severe smoking Any history of attempting to smoke cessation including, Varenicline or Bupropion tablets, Nicotine gum and nicotine patch

Design outcomes

Primary

Measure	Time frame
Smoke cessation. Timepoint: Beginning and the end of the intervention. Method of measurement: Nicotine dependence scale (NDSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehran Shayganfard

Arak University of Medical Sciences

mshayganfard@yahoo.com+98 86 3313 4715

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026